Octreotide therapy in acromegaly is associated with an increased prevalence of gall stones, which may be the result of an inhibition of gall bladder motility. Gail stone prevalence in untreated acromegalic patients relative to the general population is unknown, however, and the presence of gail stones and gail bladder motility in these patients and in acromegalic patients receiving octreotide was therefore examined. Thirteen patients with gall stone disease were also studied. Six aged 43-56 years (one woman) had undergone percutaneous cholecystolithotomy and were free of stones at the time of this study, and seven patients aged 28-78 years (four women) had gall stones in the gall bladder. Ultrasound of the gall bladder after percutaneous cholecystolithotomy showed no evidence of thickening or tethering of the gall bladder wall.
patients with a group of normal subjects and a group of non-acromegalic gall stone patients in whom impaired gall bladder motility has been implicated in the pathogenesis of stones.
Subjects and methods Nineteen normal volunteers (mean age 37, range 23-64 years, eight women) were recruited from hospital staff. None had any history of gastrointestinal or gall bladder disease and ultrasonography showed no evidence of gall stones or gall bladder pathology.
Fifty one patients with acromegaly (mean age 48, range 24-80 years, 28 women) were studied. The clinical diagnosis of acromegaly was confirmed by a 75 g glucose tolerance test during which circulating growth hormone failed to fall below 2 mU/l. The average basal serum growth hormone obtained in each patient from a five point day curve performed on samples drawn through an indwelling venous cannula over 12 hours ranged from 5 to 1135 mU/l, and no sample was <2 mU/l.
Thirteen patients with gall stone disease were also studied. Six aged 43-56 years (one woman) had undergone percutaneous cholecystolithotomy and were free of stones at the time of this study, and seven patients aged 28-78 years (four women) had gall stones in the gall bladder. Ultrasound of the gall bladder after percutaneous cholecystolithotomy showed no evidence of thickening or tethering of the gall bladder wall. 8-8 g, carbohydrate 34'3 g, Abbott laboratories, England) and the gall bladder was rescanned at 5 minute intervals for 40 minutes or until the gall bladder started to refill. The smallest gall bladder volume observed was termed the residual volume (RV). The maximal percentage emptying (%E) was calculated using the formula (I-RV/FV)x 100. The rate constant of gall bladder emptying was calculated from ln/linear regression of gall bladder volume v time. 12 Acromegalic patients taking octreotide administered the first daily injection 1 hour before the scan. The radiologist was unaware which acromegalic subjects were taking octreotide.
Gall bladder motility studies were performed in 31 patients before treatment with octreotide, and in nine ofthis group with a further six patients (total 15) also after treatment with octreotide. Among retrospectively studied patients, who had been treated with octreotide, I 1 (61%) of the 18 had gall stones. This prevalence is much higher (p<0001) than that predicted for the general population of the same age and sex using the published prevalence data in the general population (1 2 cases predicted using the Bristol data8; 1 6 cases predicted using Sirmione data9). Within these retrospectively studied patients, all but two of the subgroup of eight patients who had been on therapy with octreotide for over 36 months) mean 45-5 months, range 37-59) developed gall stones. The mean (SEM) daytime plasma growth hormone concentration (mU/l) measured on octreotide therapy was not significantly different in patients with gall stones (12-9 (3 2)) compared with those without (18-0 (7 5) g the subjects with gall stone disease is in Figure 1 . Gall bladder emptying was antly impaired in the untreated acroc patients and acromegalic patients on tide, and similar to that in gall stone :s. There was no significant difference in tal percentage emptying in the octreotide group of acromegalic patients and those ring octreotide. The rate of gall bladder ing in untreated acromegalic patients was antly less than in the normal controls (rate nt -0015/minutes v -0-040/minutes, Our data confirm previous reports that octreotide therapy is associated with an increased prevalence of gall stones and show that the duration of treatment with octreotide is important in the risk of stone formation. The high prevalence of gall stones in the retrospectively studied group is particularly convincing. Data from this group of patients suggest that the risk of gall stone formation within the first year of octreotide treatment is slight, but that this increases with time, such that gall stones are present in 75% of patients when treatment is continued for more than 3 years. The risk ofgall stone formation with octreotide therapy has been reported to be quite low in some studies,2728 and the timing of the octreotide administration in relation to meals may be an important factor. Octreotide administration after meals may result in a less profound effect on gall bladder emptying. Our patients, however, have a high prevalence of gall stones despite being instructed to take their second and third injections of octreotide mid-afternoon and late in the evening and since even small doses (in the order of 5 [.g) are capable of suppressing meal stimulated gall bladder contraction for up to 6 hours,29 it may not be possible to avoid the effect of octreotide on gall bladder motor function.
The prevalence of gall stones in the untreated acromegalic subjects is at the most only slightly greater than that in the normal population despite the fact that gall bladder function in this group is severely impaired and of the order of that found in patients with cholesterol gall stone disease. [30] [31] [32] The reason for impaired gall bladder emptying in these subjects is not clear: delayed gastric emptying may be important, although since the time course ofgall bladder emptying and refilling after the liquid meal was similar in both the untreated acromegalic patients and the normal controls it seems unlikely that this is a major factor.
In conclusion, our study has confirmed previous work that shows that octreotide therapy is associated with an increased prevalence of gall stones and that duration of treatment seems to be important. Impaired gall bladder emptying is associated with this increased risk. We have also shown, for the first time, that acromegalic patients not treated with octreotide have abnormal gall bladders which empty poorly. The reason for this is as yet undetermined.
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